Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair regrowth using 2-deoxy-d-ribose (2DDR) combined with minoxidil, with some users noting new hair growth. The original poster has been using minoxidil for 12 years and is considering combining 2DDR with finasteride, despite past side effects.

A user is considering switching from finasteride to dutasteride for hair loss at age 21, worried about potential side effects on bone and brain development. Another user shared their positive experience with dutasteride, noting minimal body hair and no side effects.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

An 18/19-year-old male started balding at 16 and initially saw hair growth with minoxidil, but results diminished over time. He switched dermatologists and is now using a regimen of topical finasteride, minoxidil, vitamin D, and supplements, hoping for better results.

A user experienced significant hair regrowth using dutasteride without side effects, starting with finasteride and not using minoxidil or dermarolling. They attributed success to a unique genetic response to DHT blockers but did not share their full regimen, frustrating others.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

The individual is experiencing hair loss and has a vitamin D deficiency, with levels at 7.49ng/ml or 26nmol/l. They are unsure if the deficiency is causing the hair loss and are seeking advice on vitamin D supplementation.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

Hair loss involves more than just DHT, with genetic factors like TRPS affecting hair follicles. Treatments such as Amplifica's AMP-601 and AMP-303 target stem cells for potential hair growth solutions.

A user shared their 20-week progress using oral finasteride (1mg) and oral minoxidil (3.3mg) for hair loss, noting significant improvement in hair thickness and coverage. Another user complimented the progress.

Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).

A 20-year-old male has been experiencing hair loss for three years due to a vitamin D deficiency and has seen no improvement after 3.5 months of taking supplements. Another person suggested that if the hair loss follows a pattern, it might be regular baldness rather than due to the deficiency.

A 21-year-old is experiencing aggressive hair loss and questions the effectiveness of finasteride after 45 days of use, with high DHT levels. A user advises that scalp DHT, not serum DHT, is important for hair loss assessment, and suggests monitoring hair improvement over time.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

Alfatradiol (0.025%) is an effective and safe treatment for androgenetic alopecia in both men and women, increasing anagen hair rates with minimal side effects. Users discuss its cost-effectiveness and ease of use compared to other treatments like finasteride and RU58841, with some combining it with stemoxydine and Minoxidil.

The user is taking 2.5 mg dutasteride and 5% minoxidil but is not seeing hair regrowth, and is considering adding RU58841. They are experiencing fatigue and low MCV/MCH, possibly related to dutasteride, and are advised to be patient, consider microneedling, and check for iron deficiency.

A 20-year-old noticed hairline changes after using testosterone and started finasteride to address it. They are considering using minoxidil but are advised to monitor progress on finasteride first before adding it.

A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.

A 42-year-old male shared his hair regrowth progress using a regimen of oral dutasteride, topical minoxidil, and finasteride, along with testosterone injections. He experienced noticeable improvement in hair growth and expressed gratitude for the support and information from the community.

A 40-year-old shared their positive experience with a second hair transplant at HDC Cyprus, involving 4148 grafts and costing around 9,000 euros. They used oral minoxidil, Dutasteride, biotin, and vitamins to aid recovery and were pleased with the results.

Hair loss can be treated by correcting glucose metabolism in hair follicles and using equol as a safer DHT blocker. Production of these treatments is starting soon, and a Discord channel is available for more information.

The user is experiencing rapid hair loss despite using dutasteride, finasteride, and minoxidil, and is concerned about high estradiol and testosterone levels. They are advised to consult an endocrinologist for potential hormonal imbalances.

A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.

A discount code for 20% off at Anageninc is shared, valid for purchasing RU58841 or Pyri from May 10-11, 2025. The conversation focuses on hair loss treatments using RU58841.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The post is an update on the user's hair loss journey. They have a strong hair follicle that has remained unaffected by hair loss for almost 3 years. The user is starting finasteride and using ketoconazole, alfatradiol, and oral castor oil for hair maintenance.